Help accelerate clinical development with ultrasensitive MRD testing
The clinical solution for MRD testing
Haystack MRD™ leverages exceptional sensitivity and specificity to accelerate clinical trials and produce insights that drive biopharma pipeline development.
Haystack MRD delivers exceptional accuracy at ultra-low ctDNA levels. The test's clean background allows for a low calling threshold, which yields high sensitivity for patient enrollment, stratification, and response monitoring.
With an error rate that is 100x lower than other sequencing methods, Haystack MRD delivers confidence in ctDNA test results.
Haystack MRD was purpose-built for granular ctDNA testing that reports variant-level results. In addition to reporting sample-level MRD status, Haystack MRD can track specific ctDNA variants for various applications, including targeted therapy guidance.
Get in touch
With our deep roots in liquid biopsy and MRD testing, Haystack Oncology is committed to providing biopharma solutions to improve patient outcomes. Let our exceptional MRD detection capabilities and team of global experts support your clinical cancer research and therapeutic development efforts.
Have questions? We would love to hear from you. Simply click the button below.
